CO SB124

Nonprofit hospitals participating in the federal 340B drug pricing program must use 340B profits to reduce out-of-pocket costs for low-income patients and are prohibited from using those profits for board compensation exceeding 35%, lobbying, advertising, tax penalties, travel/entertainment for directors, or gifts

Beginning July 1, 2026, nonprofit hospitals must submit annual transparency reports to the state department detailing 340B drug acquisition costs, payments received by payer type, prescription volumes, charity care costs, and payments to contract pharmacies and third-party administrators

The state department must compile and publish all hospital reports on a public website by September 15 each year, starting in 2026, and submit an aggregated report to the General Assembly

Manufacturers, wholesalers, and logistics providers are prohibited from restricting 340B drug access for sole community hospitals and critical access hospitals unless federally prohibited

Violations are classified as unfair and deceptive trade practices enforceable by the Attorney General, who must establish a process for individuals to report suspected violations